Voluntary nationwide recall: Atovaquone (Bionpharma – September)

Oct. 2024Pharmacy Updates

Bionpharma Inc. is recalling one lot, lot 2310083, of Atovaquone Oral Suspension, 750 mg/mL. Atovaquone is used to prevent a fungal infection called pneumocystis jirovecii pneumonia in adults and adolescents age 13 and older.

This drug is being recalled because Cohnella bacteria was found in the product. Using this contaminated drug can cause life-threatening swelling of the heart and permanent damage to the body’s soft tissue.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Atovaquone, you should stop using the product and return it to the place of purchase.

As of Sept. 17, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Bionpharma at 1-888-235-2466. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars

CME Webinar: Navigating Grief Conversations

Please join us for a live, CME-accredited webinar on Thursday, Nov. 12, 2026, that will enhance your confidence and effectiveness in supporting patients dealing with loss & grief.
Oct. 2026Education/Webinars

UPMC Health Plan Tapestry Link live training session

UPMC Health Plan Tapestry Link is scheduled to go live on Tuesday, Dec. 1, 2026. To help prepare you for this launch we will be hosting a live training session on Wednesday, Nov. 4, 2026, from noon to 1 p.m. to help you familiarize yourself with the platform. During this training we will discuss:
Sep. 2026Education/Webinars